| pubmed-article:17702032 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17702032 | lifeskim:mentions | umls-concept:C0020179 | lld:lifeskim |
| pubmed-article:17702032 | lifeskim:mentions | umls-concept:C0718066 | lld:lifeskim |
| pubmed-article:17702032 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:17702032 | pubmed:issue | 13 | lld:pubmed |
| pubmed-article:17702032 | pubmed:dateCreated | 2007-11-5 | lld:pubmed |
| pubmed-article:17702032 | pubmed:abstractText | Transcriptional dysregulation in Huntington's disease (HD) is mediated in part by aberrant patterns of histone acetylation. We performed a dose-finding study in human HD of sodium phenylbutyrate (SPB), a histone deacetylase inhibitor that ameliorates the HD phenotype in animal models. We used a dose-escalation/de-escalation design, using prespecified toxicity criteria and standard clinical and laboratory safety measures. The maximum tolerated dose was 15 g/day. At higher doses, toxicity included vomiting, lightheadedness, confusion, and gait instability. We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose-response. In conclusion, SPB at 12 to 15 g/day appears to be safe and well-tolerated in human HD. | lld:pubmed |
| pubmed-article:17702032 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17702032 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17702032 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17702032 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17702032 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17702032 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17702032 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17702032 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17702032 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17702032 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17702032 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:17702032 | pubmed:issn | 0885-3185 | lld:pubmed |
| pubmed-article:17702032 | pubmed:author | pubmed-author:KraincDimitri... | lld:pubmed |
| pubmed-article:17702032 | pubmed:author | pubmed-author:HogarthPenelo... | lld:pubmed |
| pubmed-article:17702032 | pubmed:author | pubmed-author:LovrecicLucaL | lld:pubmed |
| pubmed-article:17702032 | pubmed:copyrightInfo | 2007 Movement Disorder Society | lld:pubmed |
| pubmed-article:17702032 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17702032 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:17702032 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:17702032 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17702032 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17702032 | pubmed:pagination | 1962-4 | lld:pubmed |
| pubmed-article:17702032 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:meshHeading | pubmed-meshheading:17702032... | lld:pubmed |
| pubmed-article:17702032 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17702032 | pubmed:articleTitle | Sodium phenylbutyrate in Huntington's disease: a dose-finding study. | lld:pubmed |
| pubmed-article:17702032 | pubmed:affiliation | Department of Neurology, Oregon Health & Science University, Portland, Oregon 97239-3098, USA. hogarthp@ohsu.edu | lld:pubmed |
| pubmed-article:17702032 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17702032 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:17702032 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17702032 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17702032 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17702032 | lld:pubmed |
